[Federal Register Volume 80, Number 29 (Thursday, February 12, 2015)]
[Notices]
[Page 7871]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-02909]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-0001]


Advisory Committee Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
renewal of certain FDA advisory committees by the Commissioner of Food 
and Drugs (the Commissioner). The Commissioner has determined that it 
is in the public interest to renew the charters of the committees 
listed in the following table for an additional 2 years beyond charter 
expiration date. The new charters will be in effect until the dates of 
expiration listed in the following table. This notice is issued under 
the Federal Advisory Committee Act (5 U.S.C. app.).

DATES: Authority for these committees will expire on the dates 
indicated in the following table unless the Commissioner formally 
determines that renewal is in the public interest.

------------------------------------------------------------------------
             Name of committee                   Date of  expiration
------------------------------------------------------------------------
Cardio and Renal Drugs Advisory Committee.  August 27, 2016.
Endocrinologic and Metabolic Drugs          August 27, 2016.
 Advisory Committee.
Oncologic Drugs Advisory Committee........  September 1, 2016.
Anti-Infective Drugs Advisory Committee...  October 7, 2016.
Dermatologic and Ophthalmic Drugs Advisory  October 7, 2016.
 Committee.
Cellular, Tissue, and Gene Therapies        October 28, 2016.
 Advisory Committee.
Technical Electronic Product Radiation      December 24, 2016.
 Safety Standards Committee.
------------------------------------------------------------------------


FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Director, Advisory 
Committee Oversight and Management Staff, Food and Drug Administration, 
10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 
1-800-741-8138. For further information related to FDA advisory 
committees, please visit us at http://www.fda.gov/AdvisoryCommittees/default.htm.

    Dated: February 6, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-02909 Filed 2-11-15; 8:45 am]
BILLING CODE 4164-01-P